Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Michelson

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Pediatric Pulmonology|January 7, 2005
Bronchiolitis obliterans in childrenGeoffrey Kurland, Peter Michelson
Pediatric Transplantation|May 10, 2008
Screening for PTLD in lung and heart-lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCRPeter Michelson, Bradley Watkins, Steven A Webber, et al.
Pediatric Blood & Cancer|February 24, 2006
Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell diseaseSteven J Ambrusko, Sriya Gunawardena, Allison Sakara, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 25, 2013
Lung transplant is a viable treatment option for patients with congenital and acquired pulmonary vein stenosisAnkit Bharat, Deirdre J Epstein, Mark Grady, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 28, 2008
Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantationLara A Danziger-Isakov, Sarah Worley, Susana Arrigain, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 3, 2020
Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung diseaseSiddhartha G Kapnadak, Emily Dimango, Denis Hadjiliadis, et al.
The Lancet. Respiratory Medicine|January 5, 2025
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trialsClaire Keating, Lael M Yonker, François Vermeulen, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Pediatric Pulmonology|January 7, 2005
Bronchiolitis obliterans in childrenGeoffrey Kurland, Peter Michelson
Pediatric Transplantation|May 10, 2008
Screening for PTLD in lung and heart-lung transplant recipients by measuring EBV DNA load in bronchoalveolar lavage fluid using real time PCRPeter Michelson, Bradley Watkins, Steven A Webber, et al.
Pediatric Blood & Cancer|February 24, 2006
Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell diseaseSteven J Ambrusko, Sriya Gunawardena, Allison Sakara, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 25, 2013
Lung transplant is a viable treatment option for patients with congenital and acquired pulmonary vein stenosisAnkit Bharat, Deirdre J Epstein, Mark Grady, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 28, 2008
Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantationLara A Danziger-Isakov, Sarah Worley, Susana Arrigain, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 3, 2020
Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung diseaseSiddhartha G Kapnadak, Emily Dimango, Denis Hadjiliadis, et al.
The Lancet. Respiratory Medicine|January 5, 2025
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trialsClaire Keating, Lael M Yonker, François Vermeulen, et al.
Pageof 1